Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 15, 2021

Primary Completion Date

July 26, 2023

Study Completion Date

July 26, 2023

Conditions
Limited Stage Small Cell Lung Cancer
Interventions
DRUG

Ociperlimab

Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle

DRUG

Tislelizumab

Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle

DRUG

Concurrent Chemoradiotherapy

"Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"

Trial Locations (33)

13496

Cha Bundang Medical Center, Cha University, Gyeonggido

16247

The Catholic University of Korea, St Vincents Hospital, Suwon

16499

Ajou University Hospital, Suwon

28644

Chungbuk National University Hospital, Cheongju-si

37909

Tennessee Cancer Specialist, Knoxville

41404

Kyungpook National University Chilgok Hospital, Daegu

72300

Hanzhong Central Hospital, Hanzhong

100034

Peking University First Hospital, Beijing

100142

Beijing Cancer Hospital, Beijing

200000

Fudan University Shanghai Cancer Center, Shanghai

200032

Affiliated Zhongshan Hospital of Fudan University, Shanghai

210029

Nanjing Chest Hospital, Nanjing

221000

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

223300

Huai An First Peoples Hospital, Huaian

250000

Qilu Hospital of Shandong University, Jinan

264000

Yantai Yuhuangding Hospital, Yantai

266031

Qingdao Central Hospital, Qingdao

276001

Linyi Cancer Hospital, Linyi

300052

Tianjin Medical University General Hospital, Tianjin

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310022

Zhejiang Cancer Hospital, Hangzhou

315000

Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo

410011

The Second Xiangya Hospital of Central South University, Changsha

410013

Hunan Cancer Hospital, Changsha

430022

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

450000

Henan Cancer Hospital, Zhengzhou

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510080

The First Affiliated Hospital, Sun Yat Sen University, Guangzhou

530021

The Tumor Hospital Affiliated to Guangxi Medical University, Nanning

610041

West China Hospital, Sichuan University, Chengdu

637000

Affiliated Hospital of North Sichuan Medical College, Nanchong

650000

The Second Affiliated Hospital of Kunming Medical University, Kunming

730050

Gansu Provincial Cancer Hospital, Lanzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY